Frontiers in nutrition · 2026
Effects of collagen peptide supplementation on bone turnover, cytokine, and inflammatory markers in female distance runners: a randomized pilot study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kuhlman Nicholas M, Jagim Andrew R, Blesso Christopher N, Puglisi Michael J, Chun Ock K, Jones Margaret T, Fields Jennifer B
Аннотация
INTRODUCTION: Female distance runners are at elevated risk for impaired bone remodeling due to high mechanical loading, potential low energy availability, and sustained inflammatory stress. Collagen peptide (CP) supplementation has been proposed as a nutritional strategy to support type I collagen synthesis and modulate osteoimmune signaling; however, evidence in premenopausal endurance athletes is limited. This pilot randomized, double-blind, placebo-controlled trial examined the effects of four weeks of high-dose CP supplementation on markers of bone metabolism and inflammatory activity in endurance-trained premenopausal women.
METHODS: Twenty-two participants (18-35 years; ≥35 miles/week [>56km/week]) were randomized to CP (INT; 20 g/day) or isocaloric maltodextrin (CON). Pre- and post-intervention assessments, conducted in the early follicular phase, included serum procollagen type I N-terminal propeptide (P1NP), plasma C-terminal telopeptide of type I collagen (CTX-1), serum soluble receptor activator of nuclear factor-κB ligand (sRANKL), osteoprotegerin (OPG), the sRANKL/OPG ratio, and interleukin-6 (IL-6). Repeated-measures ANCOVAs were performed, adjusting for accumulated running distance and vitamin D status.
RESULTS: A significant group × time interaction was observed for P1NP (p = 0.04), with increases in INT and no change in CON. No significant interaction was observed for CTX-1 (p = 0.13). Significant interactions were also observed for sRANKL (p = 0.046) and IL-6 (p = 0.03). No significant interaction effects were detected for sRANKL, OPG, or the sRANKL/OPG ratio.
DISCUSSION: Short-term CP supplementation increased a marker of bone formation, altered osteoclast-related signaling, and reduced IL-6 in endurance-trained premenopausal women. These findings support the potential for CP-mediated modulation of bone turnover and inflammatory activity and warrant further investigation in larger, adequately powered trials incorporating structural bone outcomes.
METHODS: Twenty-two participants (18-35 years; ≥35 miles/week [>56km/week]) were randomized to CP (INT; 20 g/day) or isocaloric maltodextrin (CON). Pre- and post-intervention assessments, conducted in the early follicular phase, included serum procollagen type I N-terminal propeptide (P1NP), plasma C-terminal telopeptide of type I collagen (CTX-1), serum soluble receptor activator of nuclear factor-κB ligand (sRANKL), osteoprotegerin (OPG), the sRANKL/OPG ratio, and interleukin-6 (IL-6). Repeated-measures ANCOVAs were performed, adjusting for accumulated running distance and vitamin D status.
RESULTS: A significant group × time interaction was observed for P1NP (p = 0.04), with increases in INT and no change in CON. No significant interaction was observed for CTX-1 (p = 0.13). Significant interactions were also observed for sRANKL (p = 0.046) and IL-6 (p = 0.03). No significant interaction effects were detected for sRANKL, OPG, or the sRANKL/OPG ratio.
DISCUSSION: Short-term CP supplementation increased a marker of bone formation, altered osteoclast-related signaling, and reduced IL-6 in endurance-trained premenopausal women. These findings support the potential for CP-mediated modulation of bone turnover and inflammatory activity and warrant further investigation in larger, adequately powered trials incorporating structural bone outcomes.